Global Dengue Vaccine Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024
Dengue Vaccine Market
Dengue is a mosquito-borne disease caused by Dengue virus with symptoms such as high and painful fever. Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. The mosquito acts as a carrier for virus and injects the virus into the bloodstream of the humans. It cannot be transmitted from one person to another. There are only vector control measures for dengue prevention thus a dengue vaccine is helpful in the regions where the dengue outbreak is common.
This report on dengue vaccine market gives historical, current, and future market sizes (US$ million) of product types, vaccine type, end users, and geographic regions. This report studies dengue vaccine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccine market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed dengue vaccine market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.
Free sample of this report is available upon request @
The global dengue vaccine market is categorized into following topics-
- Product Type
- CYD-TDV (Dengvaxia)
- DENVax
- TetraVax-DV
- Others
- Vaccine Type
- Live Attenuated Vaccine
- Killed Vaccine
- Others
- End Users
Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs).
Free TOC of this report is available upon request @
And lastly, on the basis of geographical regions, the global dengue vaccine market is divided into following regions- North America, Europe, Asia-Pacific, the Middle East & Africa and Latin America. Asia-Pacific region expected to lead the global dengue vaccine market owing to widespread prevalence and incidence of dengue fever and a large population who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programs. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for the dengue vaccine. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programs to prevent the dengue epidemics. According to WHO estimates, there are around 50 million dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.
Some of the key players profiled in the global dengue vaccine market include Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Insitituto Butantan (Brazil), Vabiotech (Vietnam), Panacea Biotech(India), Biological E (India), GlaxoSmithKline plc (U.K) and Merck & Co. Inc. (U.S.) are few to name. Market players are focusing on developing live and killed vaccines with improved safety and efficacy to garner larger revenue share in global dengue vaccine market. The dengue vaccine market estimated to be valued at US$ 235 million in 2017 and expected to grow at CAGR 27.7%. The market for dengue vaccines projected to reach US$ 1,020 million by 2023 due to newer product launches and lack of treatment options.
Ask Analyst for Full Information about this report @
Currently, Dengvaxia is the only vaccine available for dengue prevention in the market. Dengvaxia (CYD-TDV) is a recombinant tetravalent vaccine administered in three doses in series of 0/3/6 month schedule. However, there are around five dengue vaccine candidates under development, which are showing positive results in different clinical trial phases. Furthermore, vaccines like DENVax from Takeda Pharmaceutical Company Limited is showing better clinical benefits in all age groups and have convenient dosing pattern i.e. two doses (three months apart). Developing clinically efficacious vaccines in flexible dosing regimens expected to fuel the dengue vaccine market revenue growth.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com